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Machine learning risk prediction 
model for acute coronary 
syndrome and death from use 
of non‑steroidal anti‑inflammatory 
drugs in administrative data
Juan Lu1,2,3,4, Ling Wang2,5, Mohammed Bennamoun3, Isaac Ward2, Senjian An6, 
Ferdous Sohel3,7, Benjamin J. W. Chow8, Girish Dwivedi1,4,9,10 & Frank M. Sanfilippo2,10*
Our aim was to investigate the usefulness of machine learning approaches on linked administrative 
health data at the population level in predicting older patients’ one‑year risk of acute coronary 
syndrome and death following the use of non‑steroidal anti‑inflammatory drugs (NSAIDs). Patients 
from a Western Australian cardiovascular population who were supplied with NSAIDs between 1 Jan 
2003 and 31 Dec 2004 were identified from Pharmaceutical Benefits Scheme data. Comorbidities 
from linked hospital admissions data and medication history were inputs. Admissions for acute 
coronary syndrome or death within one year from the first supply date were outputs. Machine learning 
classification methods were used to build models to predict ACS and death. Model performance was 
measured by the area under the receiver operating characteristic curve (AUC‑ROC), sensitivity and 
specificity. There were 68,889 patients in the NSAIDs cohort with mean age 76 years and 54% were 
female. 1882 patients were admitted for acute coronary syndrome and 5405 patients died within one 
year after their first supply of NSAIDs. The multi‑layer neural network, gradient boosting machine 
and support vector machine were applied to build various classification models. The gradient boosting 
machine achieved the best performance with an average AUC‑ROC of 0.72 predicting ACS and 0.84 
predicting death. Machine learning models applied to linked administrative data can potentially 
improve adverse outcome risk prediction. Further investigation of additional data and approaches are 
required to improve the performance for adverse outcome risk prediction.
Non-steroidal anti-inflammatory drugs (NSAIDs) are extensively prescribed for pain  relief1. A large number 
of structurally diverse NSAIDs with similar therapeutic effects have been developed and NSAIDs belong to the 
most widely used pharmacological drugs, both over the counter (OTC) and by  prescription2,3. However, their 
potential association with cardiovascular (CV) adverse outcomes are also well known. Multiple previous studies 
have reported an increased risk of CV events from the use of  NSAIDs1,3–6. For example, Rofecoxib, one of the 
NSAIDs we investigated, was withdrawn from the market in October 2004 after a randomised placebo-controlled 
trial showed an increased risk of CV events among  users5. Importantly, the population commonly taking NSAIDs 
is elderly individuals who have a higher risk of adverse  outcomes1,3,7.
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Adverse outcomes in older patients are a major burden in society, resulting in severe morbidity, mortality 
and significant healthcare  costs8. Older adults are nearly seven times more likely to be hospitalised due to drug-
related problems than younger  patients8,9. Thus, accurate risk prediction models for adverse outcomes of drugs 
are necessary in clinical practice to help doctors to reduce the risk in the  elderly10. A large number of surveys 
aimed to identify the key factors increasing a person’s risk of adverse outcomes have been  proposed11,12, but 
they are not suitable for predicting the individual risk of adverse events due to the considerable differences in 
diseases and drug history between patients. This motivates the machine learning based risk prediction model 
design based on patients’ comorbidity and medication history obtained from suitable data sources, preferably 
at the population level.
Machine learning is increasingly common in big data science, with rapid uptake for medical  applications13–16. 
There are advantages in using machine learning in risk predictions based on a wide array of patient  data17,18. 
These can be used as decision support tools to aid prescribing of drugs in clinical practice. On wider applica-
tion, they can be used to predict the risk of adverse outcomes of drugs at the population level. The availability of 
population-based drug dispensing data from the Pharmaceutical Benefits Scheme (PBS) in Australia, when linked 
to hospital admissions and death, offers an ideal opportunity to identify adverse outcomes following medica-
tion use at the population level. Acute coronary syndrome (ACS), consisting of acute myocardial infarction and 
unstable angina, is one of the common adverse outcomes of  NSAIDs1,19. Death is also important as studies have 
shown increased mortality associated with  NSAIDs20.
The aim of this study was to build machine learning models to predict the risk of ACS and all-cause death 
in elderly patients who were dispensed NSAIDs in Western Australia. Our motivation was to apply this as a test 
case to determine the utility of machine learning at the population level using multiple linked administrative 
datasets. We included comorbidity history and medication history for model development. All records were 
from the PBS data linked with Hospital Morbidity Data Collection (HMDC) for hospital admissions, and death 
register dataset in Western Australia. We compared the performance of different machine learning models and 
analysed the impact of features on the machine learning model.
Methods
We used administrative data and built machine learning models to predict ACS and mortality risk of patients 
who had NSAIDs dispensed from pharmacies upon presenting a prescription. As shown in Fig. 1, we selected 
our cohort from the linked administrative data, and then processed and cleaned the data for our risk prediction 
models. We then randomly split the data into training and testing sets, built the machine learning models, evalu-
ated their performance, and optimized the performance through hyperparameter tuning and feature selection.
Data sources. The study datasets were a subset of population-level data consisting of public and private 
hospital admissions for heart disease in Western Australia during 2003–2008 from the HMDC, with linked 
admission records back to 1980 and forward to  201421. These were linked to matching records from the Western 
Australian death registry to 2014, and PBS data from mid-2002 to mid-2011 from the Australian Department of 
Human Services. The HMDC and mortality data are 2 of the core datasets of the Western Australian Data Link-
age  System22. The PBS dataset contains patient-level information for medications dispensed from PBS-registered 
pharmacies in the community and in hospitals, including details such as drug name and strength, quantity sup-
plied, and supply date.
Inclusion criteria and selection. We identified patients supplied with NSAIDs at least once between 1 
Jan 2003 and 31 Dec 2004 and aged 65 or above, from the PBS dataset. All the drugs were identified by their 
Anatomical Therapeutic Chemical (ATC) code. This period, corresponding to rofecoxib being withdrawn from 
Figure 1.  The machine learning workflow and contribution of our study. The figure was created using Microsoft 
PowerPoint 365, available from: https:// office. micro soft. com/ Power Point.
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the market in October 2004, ensured that we could capture all the records of NSAIDs. The PBS dataset records 
medications where the government pays a share of the drug cost, and does not include records where the patients 
pays for the drug in full. Previous research has shown that patients aged 65 or above are mostly concessional ben-
eficiaries, and their dispensing records in the PBS data are mostly  complete23. Furthermore, most of the patients 
taking NSAIDs are also elderly and adverse outcomes are more common and serious in the elderly. Thus, the age 
of the patients in the study was restricted to 65 and above. Figure 2 shows the study timeline. The study patients 
were those with dispensing records between 1 Jan 2003 and 31 Dec 2004. Comorbidity history was identified 
using a 10-year lookback period, and drug history was determined using a 6-month lookback. ACS and all-cause 
death were identified within one year after the first NSAID supply date.
Input features. The features in our model consist of (1) patient demographic information, (2) comorbidity 
history, and (3) drug history. Demographic information includes age, gender, marital status, and Indigenous 
ethnicity. These are very common features in medical records and are considered to be strongly related to the 
patient’s health. Age was defined at the first supply date of the NSAIDs for the study cohort. Marital status and 
Indigenous ethnicity were defined at the last admission before the patients’ first NSAID supply. Comorbidity 
history and drug history are recorded based on the timeline design (Fig. 2). The history of comorbidities was 
determined from the diagnosis codes based on the International Classification of Diseases (both ICD-9-CM 
and ICD-10-AM) in the hospital admission dataset with a 10-year lookback period from the first supply date 
(see detailed list of ICD codes in Supplementary Table S1). Comorbidities included 13 features: ischaemic heart 
disease, hypertension, atrial fibrillation, diabetes, chronic obstructive pulmonary disease, peripheral vascular 
disease, stroke, chronic kidney disease, cancer, dementia, depression, heart failure, and cardiomyopathy. We 
included comorbidity history as continuous variables representing the frequency of previous admissions of each 
comorbidity within the 10-year lookback. Drug history was identified using a 6-month look back from the first 
supply date of the cohort using the PBS data, and drugs were grouped into 16 features corresponding to the 
first character of the ATC code. We also included the history of NSAIDs as 13 features corresponding to the 
13 NSAIDs investigated. Drug history was presented as continuous variables representing the total number of 
medications supplied to patients.
Outcomes. We focused on the patients’ risk of ACS and all-cause death in our study, as previous studies have 
presented the CV risks of  NSAIDs1,3–6,19,20. ACS admission was identified from the principal discharge diagnosis 
field from the HMDC records using ICD-10-AM code I20.0 for unstable angina and I21 for myocardial infarc-
tion. We also classified patients who died due to coronary heart disease causes (ICD-10-AM I20-I25) as ACS. 
Patients who had drug supplies recorded after they died were excluded. (Fig. 3). Deaths were identified from 
the death registry. We also looked at a composite outcome, including both ACS admissions and all-cause death. 
Follow-up of patients began after their first supply date and finished at 365 days after the first supply date. In 
all the records we obtained, there were some patients with the same input features but different outcomes (with 
or without the event), which interfered with the prediction results. Therefore, we excluded these records before 
training the machine learning models.
Machine learning method. We developed three machine learning models for risk prediction: gradient 
boosting machine (GBM), multi-layer neural network (MLNN) and support vector machine (SVM). These 
machine learning models perform well in clinical risk  prediction16,18,24,25. However, there is no literature explor-
Figure 2.  Timeline for study cohort showing history, exposure and follow-up periods. The first supply date for 
the COX-2 inhibitors or ibuprofen within years 2003 and 2004 was defined as t0 . The figure was created using 
Microsoft Visio 365, available from: https:// produ cts. office. com/ en/ visio/ flowc hart- softw are.
Figure 3.  Flowchart showing identification of the study cohort. ACS, acute coronary syndrome. The figure was 
created using Microsoft PowerPoint 365, available from: https:// office. micro soft. com/ Power Point.
4
Vol:.(1234567890)
Scientific Reports |        (2021) 11:18314  | https://doi.org/10.1038/s41598-021-97643-3
www.nature.com/scientificreports/
ing their performance in risk prediction for NSAIDs in a population-level study. Further details of GBM, MLNN 
(Supplementary Fig. S1) and SVM are described in the Supplementary File. All analyses and model building 
were done with Python version 3.7 and relevant libraries, including scikit-learn26, and  Keras27.
The predictive performance of models was compared by calculating sensitivity, specificity, and the area under 
the receiver operating characteristic curve (AUC-ROC). We used the Youden  index28 to identify the optimised 
threshold for the ML model predictions that would achieve a balanced sensitivity and specificity. Other meas-
ures, such as positive predictive value (PPV), negative predictive value (NPV) and F1 score were not calculated. 
These depend on the prevalence of the outcomes being measured, which is low for the ACS and death outcomes 
associated with use of NSAIDs, and will lead to distorted values for PPV, NPV and F1 score. However, sensitivity 
and specificity are not affected by the prevalence of the outcomes being measured.
For all models, we randomly split the dataset using different random states and calculated their mean perfor-
mance matrices and their 95% confidence intervals from training and evaluating the models 50 times. Once the 
outperforming model was identified, we conducted a sensitivity analysis using the individual NSAIDs testing set 
(excluding NSAIDs with less than 100 test samples) and measured its prediction performance. The randomiza-
tion and repeated experiments also reduce the potential for confounding by generating groups that are fairly 
comparable with respect to the confounding  factors29,30. The model was then compared with the Cox regression 
model based on the same features to validate our modelling and performance. We built two cox regression 
models, with one of them using the same continuous variables as we had in the machine learning models. The 
other Cox model was built on the same features, but all features were binary variables. Feature importance plots 
were generated by GBM for inspection.
Ethics approval. Human Research Ethics Committee approval was obtained from the University of Western 
Australia (RA/4/1/8065), the WA Department of Health (2014/11), and the Australian Department of Health 
(XJ-16). We were granted a waiver of informed consent. All methods were carried out in accordance with rel-
evant guidelines and regulations.
Results
Cohort characteristics. Figure 3 shows the results of each step in identifying the study cohort from the 
dataset. There were 109,101 patients supplied with NSAIDs during 2003 and 2004, and 40,212 were excluded 
due to age < 65 years or they died before the first supply (Fig. 3). Therefore, we identified 68,889 patients in the 
cohort with more than 40% as users of celecoxib and 35% users of rofecoxib. Table 1 shows patient characteris-
tics for the study groups. The mean age was 76 years, and more than 50% of the cohort was female. More males 
developed ACS, and older patients were more likely to develop ACS or die within the follow-up period. History 
of cardiovascular diseases such as ischaemic heart disease and heart failure were more common among patients 
who developed ACS than those with no ACS. The frequency of comorbidity history was higher in patients who 
died during the follow-up.
Performance of machine learning models. Table 2 shows the performance of different ML models as 
averages of the model sensitivity, specificity and AUC-ROC from training and evaluating the models 50 times. 
Among the algorithms examined, we found that GBM using features including age, sex, marital status, Indig-
enous ethnicity, comorbidity history and drug history as continuous variables achieved the best performance 
in predicting the risk of ACS (AUC 0.72, 95% CI 0.71–0.73). It slightly outperformed MLNN (AUC 0.71, 95% 
CI 0.70–0.71) and SVM (AUC 0.710, 95% CI 0.707, 0.712). The GBM had an average sensitivity of 61% (95% 
CI 60–63%) and an average specificity of 72% (95% CI 70–73%) using cutoffs selected by the Youden index. 
Machine learning models achieved similar performance in predicting all-cause mortality (AUC 0.84) and com-
posite outcome (AUC 0.78) using the same features. We also compared machine learning models with a Cox 
regression model based on the same features. The Cox regression model had a lower average AUC (0.659 95% 
CI 0.656–0.662).
Table 3 shows the performance of GBM on predicting the outcomes in patients supplied with different 
NSAIDs. It achieved the highest AUC for patients supplied with sulindac while predicting their risk of ACS 
(AUC 0.84). Its performance in predicting the risk of ACS was lower for patients supplied with piroxicam (AUC 
0.66). We found similar average AUC between different NSAIDs on all-cause mortality risk prediction, with a 
slightly lower AUC (0.79) for patients supplied with ketoprofen. The AUC was higher while predicting the risk 
of the composite outcome for patients supplied with sulindac and tiaprofenic acid.
Feature importance. Figure 4 shows the ranked feature importance for predicting adverse CV outcomes 
by GBM controlling for age, sex, comorbidity history and drug history. After controlling for these confound-
ers, cyclooxygenase-2 (COX-2) inhibitors (rofecoxib, celecoxib and meloxicam) were ranked highest among all 
NSAIDs for predicting the risk of ACS and death (Fig. 4a,b). Naproxen, ibuprofen and ketoprofen were ranked 
lower compared with COX-2 inhibitors. Due to the small sample size of some NSAIDs such as tiaprofenic acid 
and mefenamic acid, their relative feature importance was at the bottom of the list. Similar results were found 
for the composite outcome (Fig. 4c). As shown in Supplementary Fig. S2A–C, confounding features were promi-
nent, with age the most important predictor among all the features. History of cardiovascular diseases such as 
ischaemic heart disease and heart failure were also ranked high for predicting ACS, followed by drug group 
Cardiovascular system (C) and Nervous system (N). Cancer and heart failure history were important features 
associated with death, as well as drug group (N), and Musculo-skeletal system (M).
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Table 1.  Characteristics of the study cohorts for NSAIDs during 2003–2004. SD standard deviation, COPD 
chronic obstructive pulmonary disease, PVD peripheral vascular disease, ACS acute coronary syndrome. Drug 
groups: A alimentary tract and metabolism, B blood and blood forming organs, C cardiovascular system, 
D dermatologicals, G genito urinary system and sex hormones, H systemic hormonal preparations, J anti-
infectives for systemic use, L antineoplastic and immunomodulating agents, M musculo-skeletal system, N 
nervous system, P antiparasitic products, R respiratory system, S sensory organs, V various.
Features
Total cohort ACS All-cause death
No. of patients (%) n = 68 
889
No. of patients (%) 
n = 2757 (4.0%) p-value
No. of patients (%) 
n = 5405 (7.8%) p-value
Age (years, mean[SD]) 76.0 (7.2) 78.8 (8.0)  < 0.0001 80.9 (7.8)  < 0.0001
Female 37 389 (54.3) 1324 (48.0)  < 0.0001 2733 (54.3)  < 0.0001
Celecoxib 29 774 (43.2) 1204 (43.7) 0.6 2373 (43.9) 0.3
Rofecoxib 24 432 (35.5) 953 (34.6) 0.3 1851 (34.3) 0.051
Indometacin 4088 (5.9) 180 (6.5) 0.2 370 (6.9) 0.004
Sulindac 286 (0.4) 11 (0.4) 0.9 29 (0.5) 0.1
Diclofenac 11 660 (16.9) 422 (15.3) 0.02 705 (13.0)  < 0.0001
Diclofenac, combinations 18 (0.03)  < 5  < 0.0001  < 5 0.2
Piroxicam 3414 (5.0) 130 (4.7) 0.6 203 (3.8)  < 0.0001
Meloxicam 12 982 (18.8) 434 (15.7)  < 0.0001 686 (12.7)  < 0.0001
Ibuprofen 4305 (6.3) 161 (5.8) 0.4 319 (5.9) 0.3
Naproxen 5883 (8.5) 214 (7.8) 0.1 435 (8.1) 0.2
Ketoprofen 1951 (2.8) 65 (2.4) 0.1 122 (2.3) 0.008
Tiaprofenic acid 398 (0.6) 10 (0.4) 0.1 34 (0.6) 0.6
Fenamates 46 (0.07)  < 5 0.9  < 5 0.4
Comorbidity history
Ischemic heart disease 14 445 (21.0) 1031 (37.4)  < 0.0001 1150 (21.3) 0.6
Hypertension 1091 (1.6) 52 (1.9) 0.2 113 (2.1) 0.002
Atrial fibrillation 3468 (5.0) 198 (7.2)  < 0.0001 390 (7.2)  < 0.0001
Diabetes 3779 (5.5) 186 (6.8) 0.003 409 (7.6)  < 0.0001
COPD 3659 (5.3) 255 (9.3)  < 0.0001 624 (11.5)  < 0.0001
PVD 3226 (4.7) 277 (10.1)  < 0.0001 474 (8.8)  < 0.0001
Stroke 2545 (3.7) 164 (6.0)  < 0.0001 425 (7.9)  < 0.0001
Chronic kidney disease 1337 (1.9) 78 (2.8)  < 0.0001 159 (2.9)  < 0.0001
Cancer 3049 (4.4) 98 (3.6) 0.02 747 (13.8)  < 0.0001
Dementia 386 (0.6) 27 (1.0) 0.003 140 (2.6)  < 0.0001
Depression 831 (1.2) 43 (1.6) 0.08 94 (1.7) 0.0002
Heart failure 2474 (3.6) 335 (12.2)  < 0.0001 629 (11.6)  < 0.0001
Cardiomyopathy 136 (0.2) 9 (0.3) 0.1 19 (0.4) 0.008
Drug history
Drug group A 42 495 (61.7) 1868 (67.8)  < 0.0001 4032 (74.6)  < 0.0001
Drug group B 22 848 (33.2) 1214 (44.0)  < 0.0001 2352 (43.5)  < 0.0001
Drug group C 57 953 (84.1) 2389 (86.7) 0.0002 4496 (83.2) 0.05
Drug group D 13 710 (19.9) 546 (19.8) 0.9 1128 (20.9) 0.06
Drug group G 6924 (10.1) 243 (8.8) 0.03 536 (9.9) 0.7
Drug group H 12 275 (17.8) 520 (19.6) 0.01 1494 (27.6)  < 0.0001
Drug group J 30 857 (44.8) 1336 (48.5)  < 0.0001 3151 (58.3)  < 0.0001
Drug group L 3192 (4.6) 131 (4.8) 0.8 585 (10.8)  < 0.0001
Drug group M 29 698 (43.1) 1152 (41.8) 0.2 1935 (35.8)  < 0.0001
Drug group N 46 410 (67.4) 2075 (75.3)  < 0.0001 4517 (83.6)  < 0.0001
Drug group P 5829 (8.5) 290 (10.5)  < 0.0001 593 (11.0)  < 0.0001
Drug group R 13 747 (20.0) 640 (23.2)  < 0.0001 1456 (26.9)  < 0.0001
Drug group S 21 652 (31.4) 933 (33.8) 0.005 1919 (35.5)  < 0.0001
Drug group V 2554 (3.7) 109 (4.0) 0.5 261 (4.8)  < 0.0001
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Discussion
This study presents a set of machine learning models for predicting the risk of ACS and all-cause death after 
dispensing of NSAIDs using data from PBS, HMDC and death in Western Australia. We focused specifically 
on elderly patients (age ≥ 65 years) who had at least one NSAID supply. The prediction is based on the features 
including age, sex, medication history and disease history, which are routinely collected in administrative data. 
This approach encompasses a wide array of patients to reflect the population of patients taking NSAIDs in 
Western Australia. The machine learning based predictive models showed greater sensitivity, specificity and 
AUC-ROC values compared with the classical Cox-regression approach. GBM presented the best predictive 
performance for the machine learning models we tested.
Several studies have reported the risk of adverse outcomes with NSAIDs, and rofecoxib was withdrawn from 
the market due to its increased risk of CV outcomes. Our models predict ACS, all-cause death and composite 
outcome. The performance for predicting death was the best with AUC-ROC values ranging from 0.76 (Cox 
regression) to 0.84 (GBM). This demonstrates that the predictive models built based on administrative data work 
well and can predict the risk of death. The performance of the ACS risk prediction was lower, with AUC rang-
ing from 0.66 (Cox) to 0.72 (GBM). The performance may be limited by the low event rate of ACS (4%), which 
makes the class distribution highly imbalanced. As shown in Table 2, GBM has slightly outperformed MLNN 
and SVM for predicting the risks of ACS, and SVM for predicting the risks of ACS and death. This difference 
may result from the nature of the boosting power in GBM, which is an ensemble method using many trees to 
make a decision as it gains power by repeating itself. MLNN is also a powerful model as it can learn complex data 
representations from underlying data, but is prone to  overfitting31. Other studies have also found GBM can result 
in higher prediction accuracies compared with MLNN and  SVM32,33. We considered the range of AUC-ROC we 
measured to be of moderate to high accuracy in predicting the risk of ACS or death in this population. While an 
ideal precision would be an AUC-ROC > 0.90, such high values are not easy to achieve in medical applications 
Table 2.  Performance of machine learning models and Cox regression measured by sensitivity, specificity, and 
AUC-ROC. *Cox model with binary variables.
Models Performance metrics ACS (95% CI) All-cause death (95% CI) ACS or All-cause death (95% CI)
GBM
Sensitivity 0.61 (0.60, 0.63) 0.78 (0.78, 0.79) 0.68 (0.67, 0.69)
Specificity 0.72 (0.70, 0.73) 0.74 (0.73, 0.75) 0.75 (0.74, 0.75)
AUC-ROC 0.72 (0.71, 0.72) 0.837 (0.836, 0.839) 0.780 (0.778, 0.781)
MLNN
Sensitivity 0.61 (0.60, 0.63) 0.76 (0.75, 0.76) 0.69 (0.68, 0.70)
Specificity 0.70 (0.69, 0.71) 0.76 (0.75, 0.77) 0.75 (0.74, 0.75)
AUC-ROC 0.70 (0.70, 0.71) 0.834 (0.833, 0.836) 0.778 (0.776, 0.780)
SVM
Sensitivity 0.61 (0.60, 0.62) 0.74 (0.73, 0.75) 0.70 (0.69, 0.71)
Specificity 0.72 (0.71, 0.73) 0.75 (0.74, 0.75) 0.73 (0.72, 0.74)
AUC-ROC 0.710 (0.707, 0.712) 0.813 (0.812, 0.814) 0.777 (0.776, 0.779)
Cox Regression
Sensitivity 0.62 (0.60, 0.64) 0.71 (0.70, 0.72) 0.66 (0.66, 0.67)
Specificity 0.63 (0.61, 0.65) 0.69 (0.67, 0.70) 0.66 (0.65, 0.66)
AUC-ROC 0.659 (0.656, 0.662) 0.76 (0.75, 0.76) 0.711 (0.710, 713)
Cox regression*
Sensitivity 0.638 (0.602, 0.674) 0.726 (0.710, 0.742) 0.653 (0.641, 0.665)
Specificity 0.66 (0.625, 0.694) 0.729 (0.712, 0.746) 0.728 (0.718, 0.739)
AUC-ROC 0.695 (0.688, 0.702) 0.795 (0.793, 0.797) 0.750 (0.745, 754)
Table 3.  Risk prediction performance of GBM models (AUC-ROC 95% CI) for different NSAIDs. NSAID 
non-steroidal anti-inflammatory drug, GBM gradient boosting machine.
NSAID ACS All-cause death ACS or All-cause death
Indometacin 0.71 (0.70, 0.72) 0.81 (0.80, 0.81) 0.77 (0.77, 0.78)
Sulindac 0.84 (0.78, 0.89) 0.82 (0.80, 0.84) 0.82 (0.80, 0.84)
Diclofenac 0.67 (0.66, 0.68) 0.80 (0.79, 0.80) 0.74 (0.74, 0.75)
Piroxicam 0.66 (0.65, 0.68) 0.80 (0.79, 0.81) 0.73 (0.72, 0.74)
Meloxicam 0.70 (0.69, 0.70) 0.80 (0.80, 0.81) 0.75 (0.74, 0.75)
Ibuprofen 0.71 (0.70, 0.73) 0.82 (0.81, 0.82) 0.76 (0.75, 0.77)
Naproxen 0.71 (0.70, 0.72) 0.82 (0.81, 0.82) 0.77 (0.77, 0.78)
Ketoprofen 0.71 (0.69, 0.73) 0.79 (0.78, 0.80) 0.73 (0.72, 0.74)
Tiaprofenic acid 0.77 (0.72, 0.82) 0.85 (0.83, 0.87) 0.83 (0.80, 0.85)
Rofecoxib 0.710 (0.705, 0.714) 0.821 (0.819, 0.823) 0.78 (0.77, 0.78)
Celecoxib 0.72 (0.71, 0.72) 0.811 (0.809, 0.813) 0.772 (0.770, 0.774)
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of machine learning due to the variations in patient characteristics we see in humans. Furthermore, this is our 
initial investigation on the potential for machine learning models to be applied for prediction of ACS and all-
cause death using population-level administrative data. Further work needs to be done to determine if model 
performance can be improved, especially if other datasets can be added at the population level. We acknowledge 
that the outputs from the machine learning models do not necessarily suggest a causal link between the drug 
and the ACS admission or death. Instead, its purpose is to create an alert so that humans (clinicians, researchers, 
administrators) can investigate further and make a decision on whether the risk requires clinical or regulatory 
action. Hence, the machine learning application here will have clinical value as a decision support tool.
Risk prediction models have been used on different data sources (e.g. electronic medical record, adminis-
trative data) to identify risk of adverse outcomes for drugs. For example, predicting opioid overdose risk on 
administrative data with opioid prescriptions using deep neural networks and  GBM34, predict adverse drug 
reactions from ICD-10 codes using machine learning  models35 and comparing logistic regression with machine 
learning in predicting the risk of death from drug  intoxication36. The AUC-ROC of the models from these studies 
ranged from 0.69 to 0.91. Our study made use of multiple linked administrative datasets, focusing on drugs and 
outcomes, and our machine learning risk prediction models achieved a range of AUC-ROC from 0.70 to 0.84. 
This is consistent with the performance attained in the previous studies reported above. Moreover, these studies 
found that the machine learning approach did not show better performance than a classical generalised regres-
sion  approach17,37. However, our machine learning models performed better than the Cox regression models. 
Figure 4.  Ranking of NSAID feature importance from the GBM prediction models for adverse cardiovascular 
outcomes controlling for age, sex, comorbidity history and drug history. (a) Feature importance for ACS; (b) 
Feature importance for all-cause death; (c) Feature importance for the composite outcome (ACS or all-cause 
death). The figure was created using scikit-learn26.
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This could be because most of the input features in our model were continuous variables, and machine learning 
models outperform on complex variables.
To our knowledge, there are no studies that explore the predictive capabilities of machine learning models for 
ACS and all-cause death in patients supplied with NSAIDs. Our study has several strengths. The risk prediction 
model we developed can be used to identify specific CV adverse outcomes of NSAIDs. The models can inform 
doctors on which NSAID has the lowest risk of these CV outcomes based on individual patient’s medication his-
tory and disease history. Moreover, our models have been developed using population-based datasets to identify 
patients with a high risk of adverse outcomes.
Our study found that the inclusion of demographic features such as marital status, Indigenous ethnicity 
from linked hospital admissions data improved the performance of the prediction models. The average AUC 
was similar for predicting ACS (AUC 0.71). However, the performance was higher while predicting the risk of 
all-cause mortality (AUC 0.81 vs 0.84) and composite outcome (AUC 0.77 vs 0.78), with no overlap in their 
confidence intervals. Previous studies have shown that marital status is associated with adverse cardiovascular 
outcomes and mortality was higher in an unmarried  population38,39. Studies have also shown that Indigenous 
Australians have a greater risk of cardiovascular disease and  death40,41.
We extracted additional features from the hospital admissions dataset, including patients’ previous length 
of stay (days) in the hospital for each comorbidity, and the number of days patients spent in intensive care units 
(ICU) before their first supply. This set of features were presented as continuous variables. We included this set 
of features to test whether it would improve the risk prediction. However, there were no performance gains by 
adding continuous variables such as length of hospital stay of previous comorbidities and days in ICU. The AUCs 
of all the outcomes were similar to models that did not include these extra features. Hence, we dropped these 
features to reduce model complexity.
In our study, we observed minimal performance improvement when using binary variables for comorbidities 
or drug history, indicating the presence of comorbidities and history of drugs. However, ML models achieved 
better performance than Cox regression when we used continuous variables for total counts of medication his-
tory and comorbidity history. This may be because machine learning approaches do not assume linearity for a 
predictor-outcome association. They are more adept at generating predictions based on continuous  variables42.
Our machine learning model ranked COX-2 inhibitors higher among other NSAIDs for ACS risk predic-
tion. Multiple previous studies have reported an increased risk of CV events from the use of selective COX-2 
 inhibitors1,3–6. Rofecoxib was withdrawn from markets based on evidence that showed an increased risk of  ACS5. 
Naproxen and ibuprofen have been reported in several studies to be NSAIDs with less  risk1,43. Compared with 
other popular NSAIDs, the rank of naproxen and ibuprofen was lower in our study, which is consistent with 
previous research. A previous study has confirmed that heart failure substantially increases the risk of  death44. 
This verifies that our machine learning model is reliable in ranking feature importance as it showed the same 
relationship.
Despite the value of this study, there are some limitations. As with all administrative database studies, this 
study relies on the accuracy of administrative coding of diagnoses and procedures. However, the point of our 
study is that is makes use of multiple administrative datasets, which are large datasets that capture information 
at the population level. Despite whatever issues there may be with potential coding errors, we need these types of 
datasets to be able to adequately build a machine learning solution with potential for patient risk management. 
The PBS dataset did not include all dispensing supplies of NSAIDs such as ibuprofen, as this is also available 
over the counter. Moreover, the PBS dataset did not contain information about the actual drug dosage. Hence, 
in our study, we calculated the total number of supplied scripts rather than the dose used. In our study, we used 
state-level linked data to predict patients’ adverse CV outcomes after their NSAIDs supply. The models can be 
further extended to national linked data in the future. Also, for general applicability, the models can be potentially 
extended to other drugs or drug groups and different outcomes, and this can also be tested in future studies.
Implementing ML models on linked administrative data, including pharmacy claims (e.g. PBS), morbidity, 
and mortality has the potential to identify patients supplied with NSAIDs that may have a high risk of adverse CV 
outcomes. These can then be monitored closely by humans. Further investigation of additional data is required to 
validate the ML prediction performance on patients’ risk of CV adverse outcomes using population-level linked 
data. At this early stage our models were built with specific inputs from the research team, including looking 
at a specific follow-up period from NSAID use. However, further research will move towards more autonomy 
where the machine learning models will decide which drugs are potential problems and flag them for further 
investigation.
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